Flutemetamol F 18

Flutemetamol F 18

SCHEMBL10032147

CNc1ccc(-c2nc3ccc(O)cc3s2)cc1[18F]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
APP P05067 18/20 1.00
SULT1A1 P50225 4/20 0.66
MAPT P10636 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flutemetamol F 18 SCHEMBL30668500 1.00 APP (1.00) APPSULT1A1MAPT
Flutemetamol SCHEMBL10032130 1.00 APP (1.00) APPSULT1A1MAPT
Flutemetamol F 18 SCHEMBL29363499 1.00 APP (1.00) APPSULT1A1MAPT
SCHEMBL5958763 0.87 APP (0.77) APPSULT1A1MAPT
SCHEMBL14788828 0.86 APP (0.75) APPSULT1A1MAPT
SCHEMBL15604181 0.86 APP (0.75) APPMAPT
SCHEMBL13167852 0.85 APP (0.73) APPSULT1A1MAPT
SCHEMBL2061295 0.85 APP (1.00) APPSULT1A1MAPT
SCHEMBL12227066 0.85 APP (1.00) APPSULT1A1MAPT
SCHEMBL13806265 0.84 APP (0.73) APPSULT1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12514937-B2 Methods for detecting CCR2 receptors WASHINGTON UNIVERSITY (US) 2026-01-06 US claimed
EP-4330662-B1 ANALYTICAL HPLC GE HEALTHCARE LTD (GB) 2025-09-03 EP claimed
US-20250229109-A1 MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES INSIGHTEC LTD (IL) 2025-07-17 US claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
WO-2025054524-A1 METHOD FOR DIAGNOSING AMYLOID DISEASES UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) 2025-03-13 WO claimed
EP-4496618-A2 MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES Insightec Ltd. (IL) 2025-01-29 EP claimed
US-20240302338-A1 ANALYTICAL HPLC GE HEALTHCARE LTD (GB) 2024-09-12 US claimed
US-11964020-B2 Method for removing acetaldehyde GE HEALTHCARE LIMITED (GB) 2024-04-23 US claimed
EP-4330662-A1 ANALYTICAL HPLC GE Healthcare Limited (GB) 2024-03-06 EP claimed
WO-2023180811-A2 MONITORING TISSUE PERMEABILITY DURING ULTRASOUND PROCEDURES INSIGHTEC LTD. (IL) 2023-09-28 WO claimed
US-11756193-B2 Method and apparatus for diagnosing Alzheimer's disease using PET-CT image SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) 2023-09-12 US claimed
EP-4190242-A1 METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING PET-CE IMAGE AND APPARATUS THEREOF Samsung Life Public Welfare Foundation (KR) 2023-06-07 EP claimed
US-20230153991-A1 METHOD AND APPARATUS FOR DIAGNOSING ALZHEIMER'S DISEASE USING PET-CT IMAGE SAMSUNG LIFE PUBLIC WELFARE FOUNDATION (KR) 2023-05-18 US claimed
WO-2022229155-A1 ANALYTICAL HPLC GE HEALTHCARE LIMITED (GB) 2022-11-03 WO claimed
US-20220305126-A1 METHOD FOR REMOVING ACETALDEHYDE GE HEALTHCARE LIMITED (GB) 2022-09-29 US claimed
WO-2022030692-A1 METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE USING PET-CE IMAGE AND APPARATUS THEREOF 사회복지법인 삼성생명공익재단 2022-02-10 WO claimed
EP-4744053-A1 SYSTEMS AND METHODS FOR PREDICTING BRAIN TAU OR AMYLOID LEVELS Eisai R&D Management Co., Ltd. (JP) 2026-05-20 EP disclosed
EP-4743785-A1 ANTIMICROBIAL PEPTIDES Eisai R&D Management Co., Ltd. (JP) 2026-05-20 EP disclosed
US-20080286202-A1 Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition UNIVERSITY OF PITTSBURGH (US) 2008-11-20 US disclosed
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies UNIVERSITY OF PITTSBURGH 2008-09-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220305126-A1 METHOD FOR REMOVING ACETALDEHYDE ALDH2, ALDH1A1, ADH1A APP 3605/4885SULT1A1 437/4885MAPT 2218/4885
US-11964020-B2 Method for removing acetaldehyde ALDH2, ALDH1A1, ADH1A APP 3605/4885SULT1A1 437/4885MAPT 2218/4885
US-20080219931-A1 Amyloid Imaging as a Surrogate Marker for Efficacy of Anti-Amyloid Therapies TTR, APP, SAAL1 APP 2/4885SULT1A1 2536/4885MAPT 14/4885
US-20080286202-A1 Method of Diagnosing Prodromal Forms of Diseases Associated With Amyloid Deposition PSEN2, PSEN1, APP APP 3/4885SULT1A1 4158/4885MAPT 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.